Breast Cancer | Specialty

Dr. Yardley on BOLERO-2 Results for HR+ Breast Cancer

November 29th 2017

Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses the BOLERO-2 results for patients with hormone receptor (HR)-positive breast cancer.

Expert Emphasizes Importance of Neoadjuvant Therapy in HER2+ Breast Cancer

November 29th 2017

Patrick Borgen, MD, discusses the importance of neoadjuvant therapy in the treatment of patients with HER2-positive breast cancer.

Dr. Pusztai on Challenges With Neoadjuvant HER2 Therapy

November 28th 2017

Lajos Pusztai, MD, professor of medicine, chief of Breast Medical Oncology, Yale Cancer Center and Yale School of Medicine, discusses the challenges facing neoadjuvant treatment of patients with HER2-positive breast cancer

Adjuvant Treatment Evolving for HER2+ Breast Cancer

November 27th 2017

Sara M. Tolaney, MD, discusses the state of adjuvant treatment for patients with HER2-positive breast cancer.

Expert Highlights Expanding Options for HER2+ Breast Cancer

November 27th 2017

Lajos Pusztai, MD, discusses neoadjuvant and adjuvant treatment decisions for patients with HER2-positive breast cancer, as well as the potential of immunotherapy in the metastatic setting.

Expert Shares How CDK 4/6 Inhibitors Broke the Mold in HR+/HER2- Breast Cancer

November 22nd 2017

Richard S. Finn, MD, discusses the evolution of CDK 4/6 inhibition in the field of breast cancer and appropriate patient selection for this type of therapy.

Dr. Melisko on Duration of Aromatase Inhibitor Use in Breast Cancer

November 21st 2017

Michelle E. Melisko, MD, clinical professor of medicine, University of California, San Francisco (UCSF), explains the discussion around duration of use of aromatase inhibitors in patients who have estrogen receptor-positive breast cancer.

Potential in the MONALEESA-7 and MONALEESA-3 Trials

November 21st 2017

CDK4/6 Inhibitors: The Differential Value of Ribociclib

November 21st 2017

CDK4/6 Inhibitors: Changing the Treatment Landscape

November 21st 2017

Dr. Borgen on Advancements With HER2+ Breast Cancer

November 17th 2017

Patrick Borgen, MD, chair, Department of Surgery, director, Breast Center, Maimonides Medical Center, discusses advancements in the treatment landscape of HER2-positive breast cancer.

Novel Hormone Strategies Gain Ground in Breast Cancer

November 16th 2017

Although hormone-targeting therapies have been a long-established strategy for the treatment of estrogen receptor (ER)-positive breast cancer, more than 20% of patients with early-stage disease relapse and those who progress to a metastatic stage eventually die from their illness.

FDA Approves Faslodex/Abemaciclib for HR+/HER2- Breast Cancer

November 15th 2017

The FDA has approved fulvestrant (Faslodex) for use in combination with the CDK4/6 inhibitor abemaciclib (Verzenio) to treat patients with HR+/HER2- advanced or metastatic breast cancer who have progressed after endocrine therapy.

Dr. Rugo Discusses Immunotherapy in TNBC

November 15th 2017

Hope Rugo, MD, professor of medicine, director of the Breast Oncology Clinical Trials Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses immunotherapy in triple-negative breast cancer.

Dr. Brufsky Discusses Pertuzumab in HER2+ Breast Cancer

November 14th 2017

Adam M. Brufsky, MD, PhD, professor of medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses pertuzumab (Perjeta) in HER2-positive breast cancer.

Soft Tissue Sarcoma: An Increasing Number of Options

November 14th 2017

Second-Line Therapy Options: Role of Trabectedin

November 14th 2017

Soft Tissue Sarcoma: Decisions Following Progression

November 14th 2017

Changing Treatment Landscape in Soft Tissue Sarcoma

November 14th 2017

Olaratumab's Role in Soft Tissue Sarcoma

November 14th 2017